Daniel de Boer, ProQR CEO (via YouTube)
February 11, 2022 10:40 AM ESTUpdated 11:35 AM
R&D

In lat­est an­ti­sense fail­ure, Pro­QR's rare eye dis­ease treat­ment falls flat

Jason Mast

Editor

It’s been a bad 12 months for an­ti­sense tech­nol­o­gy.

Pro­QR, an RNA-fo­cused start­up, an­nounced Fri­day that its lead can­di­date for one form of a rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times